The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. clinical trials
13 indexed studies · 0 currently recruiting
- CompletedPhase I
Phase I trial: CA47303
This early-stage study, called CA47303, is looking for healthy women aged 18 to 45. It's designed to understand how a new investigational treatment works in the body and if it's safe. Details about the treatment will be made public later.
For: Healthy volunteersUnited Kingdom · Northern Ireland - RecruitingPhase I
Evaluation of NBI-1117570 in adults with stable schizophrenia
This study is testing a new medicine, NBI-1117570, for adults who have schizophrenia and are feeling stable. We want to see if it's safe, how much of it stays in the body, and what effects it has. The full details will be released in about two and a half years after the study finishes.
For: SchizophreniaUnited Kingdom · England - CompletedPhase I
Pharmacokinetic study to the open-label Phase of NUC-5/primary sclerosing cholangitis study
This early-stage study is looking at a new medicine called NUC-5 for a liver condition called primary sclerosing cholangitis. We don't have all the details yet, but they will be made public later. The study is checking how the medicine moves through the body.
For: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.United Kingdom · England - CompletedPhase I
Phase I Trial: 36414 (SUDO-550-102)
This early-stage study is looking for healthy women aged 18-55 to help test a new medicine or treatment. The full details are not yet public, but it's an important step in making sure new healthcare options are safe and effective.
For: N/A - healthy volunteersUnited Kingdom · Wales - CompletedPhase I
Phase 1 Trial: 36342 (DT-101/102)
This is a very early stage clinical trial, called a Phase 1 study, looking into a new treatment marked as DT-101/102. The aim is to understand how safe the treatment is and if it has any side effects. Full details about it will be shared later, after the study finishes.
For: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.United Kingdom · Wales - CompletedPhase I
Pilot phase I, safety and pharmacokinetic study in healthy participants
This early-stage study is testing a new treatment or medicine in healthy people for the very first time. Doctors want to check if it's safe to use and how the body handles it. More details about the study will be shared publicly later on.
For: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.United Kingdom · England - RecruitingPhase I
Phase 1 Trial: 36024 (SYX-5219-101)
This is a very early-stage medical study, called a Phase 1 trial. Researchers are testing a new treatment, SYX-5219-101. We don't have many details yet because the full information will be made public later, but it involves people aged 18 to 65. Its main goal is to check safety.
For: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.United Kingdom · Wales - RecruitingPhase II
Phase II trial: ETH47-201
This is a Phase II clinical trial, ETH47-201. Right now, full details about the study, including what it's testing and for what conditions, are not publicly available. This is because the Health Research Authority (HRA) has allowed the researchers to delay publishing this information for up to 30 months after the trial finishes.
For: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has endedUnited Kingdom · England - RecruitingPhase II
Phase II trial code: 1066
This is a Phase II study, meaning it's an early-stage trial. We can't share many details yet because the Health Research Authority (HRA) has asked us to wait. The full information will be available within 30 months after the study finishes. It involves people aged 40 to 85, both men and women.
For: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.United Kingdom · Denmark · Netherlands - RecruitingPhase I
Phase I Trial: 36540 (DF-PK-01)
This is an early-stage study (Phase I) looking into a new treatment. The full details are not yet available but will be shared within 30 months after the study finishes. It involves people aged 20 to 65.
For: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.United Kingdom · Wales - CompletedPhase I
Phase 1 Trial: EMP-012-1
This early-stage study, called EMP-012-1, is looking into a new treatment. Because it's very early research, the full details of who can join and what it involves aren't public yet. This information will be shared later, once the study is further along.
For: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.United Kingdom · England · Australia - CompletedPhase I
Phase I Trial: 36676 (P2-101-301P)
This early-stage study is looking at a new treatment. We don't have all the details yet because the information will be published later. It's for adults aged 18 to 55.
For: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.United Kingdom · Wales - RecruitingPhase I
Phase I trial: Ocular Technology Group International
This early-stage study is looking into a new treatment from Ocular Technology Group International. Since it's a very new study, many details are not yet public, but more information will become available within 30 months after the study finishes. It's for people aged 40 to 80.
For: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.United Kingdom · England